Seel,

What is your take regarding the info gov found on clinicaltrials.gov that showed a number of additional sub-investigators have been put on the rolls and each seems to be a specialist in a different line of cancer?   Is the additon of new subs a usual occurrence in trials or would you say it portends some positive findings or expectations or just a general expansion of the scope of the trial?

TIA